Allurion Technologies Hits 52-Week Low at $1.80 Amidst Major Decline

Allurion Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.80 as of October 30, 2025. This significant decline marks a staggering 93.85% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance, which has seen an 18.13% increase during the same period.
The company's market capitalization stands at approximately USD 17 million, reflecting its microcap status. Allurion Technologies has been grappling with financial difficulties, evidenced by a negative book value and a weak ability to service its debt, highlighted by an average EBIT to interest ratio of -13.96. The firm has reported losses and carries a negative net worth, raising concerns about its long-term viability.

In its latest financial results, the company reported net sales of USD 3.38 million, the lowest in recent quarters, alongside an 11.18% year-over-year increase in raw material costs. With a return on equity of 68.55%, the company faces significant challenges ahead, as it continues to underperform against the broader market benchmarks.